KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Operating Margin (2017 - 2025)

Aquestive Therapeutics has reported Operating Margin over the past 9 years, most recently at 221.58% for Q4 2025.

  • Quarterly results put Operating Margin at 221.58% for Q4 2025, down 10716.0% from a year ago — trailing twelve months through Dec 2025 was 159.5% (down 10605.0% YoY), and the annual figure for FY2025 was 159.5%, down 10605.0%.
  • Operating Margin for Q4 2025 was 221.58% at Aquestive Therapeutics, down from 89.63% in the prior quarter.
  • Over the last five years, Operating Margin for AQST hit a ceiling of 0.27% in Q2 2024 and a floor of 325.85% in Q2 2021.
  • Median Operating Margin over the past 5 years was 84.5% (2022), compared with a mean of 101.59%.
  • Peak annual rise in Operating Margin hit 28456bps in 2021, while the deepest fall reached -40485bps in 2021.
  • Aquestive Therapeutics' Operating Margin stood at 105.33% in 2021, then increased by 5bps to 100.29% in 2022, then soared by 70bps to 29.62% in 2023, then plummeted by -286bps to 114.43% in 2024, then plummeted by -94bps to 221.58% in 2025.
  • The last three reported values for Operating Margin were 221.58% (Q4 2025), 89.63% (Q3 2025), and 113.65% (Q2 2025) per Business Quant data.